some thoughts:
The extraordinary scenario that Chinese vaccine developers have to conduct Phase 3 trials abroad is challenging, but also carries some PR rewards, given the widespread distrust in Chinese official numbers.
It's challenging because the logistics must be more

difficult for Chinese vaccine developers and regulators, who have to rely on health professionals and infrastructure in Bahrain, Brazil, Turkey, and UAE to conduct the Phase 3 trials. It would certainly be much easier to do the trials in China, but that's no longer feasible

since there are simply too few cases in China to test the Chinese vaccines.
The rewards would be that since the implementation of the trials are out of Chinese hands, any suspicion of the behind-the-scenes manipulation of data should decline considerably, especially against the

backdrop that there is persistent, widespread distrust towards Chinese official numbers in the Western countries.

Instead of Beijing announcing the efficacy numbers of Chinese vaccines, it's now Turkey/UAE/Brazil/Bahrain announcing their own numbers.

Unless

Unless you somehow believe Beijing miraculously got to all of them, this actually could be a good thing from a narrowly public relations perspective.